Heptabarb
 | |
| Systematic (IUPAC) name | |
|---|---|
| 5-cyclohept-1-en-1-yl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione | |
| Clinical data | |
| |
| |
| Oral[1] | |
| Pharmacokinetic data | |
| Bioavailability | 83%[1] |
| Metabolism | Hepatic |
| Half-life | 6.1-11.2 hours[1] |
| Excretion | Renal[1] |
| Identifiers | |
| 509-86-4 | |
| N05CA11 | |
| PubChem | CID 10518 |
| DrugBank |
DB01354  |
| ChemSpider |
10081 |
| UNII |
V10R70ML23 |
| KEGG |
C17725 |
| ChEMBL |
CHEMBL468837 |
| Synonyms | G-475 |
| Chemical data | |
| Formula | C13H18N2O3 |
| 250.294 g/mol | |
|
SMILES
| |
| |
| (what is this?) (verify) | |
Heptabarb (INN; Eudan, Medapan, Medomin, Noctyn), also known as heptabarbitone (BAN) or heptabarbital, is a sedative and hypnotic drug of the barbiturate family.[2][3] It was previously used in Europe for the treatment of insomnia from the 1950s onwards, but has since been discontinued.[2][3]
See also
References
- ↑ 1.0 1.1 1.2 1.3 Breimer DD, de Boer AG (December 1975). "Pharmacokinetics and relative bioavailability of heptabarbital and heptabarbital sodium after oral administration to man". European Journal of Clinical Pharmacology 9 (2-3): 169–78. doi:10.1007/bf00614014. PMID 9299.
- ↑ 2.0 2.1 C. R Ganellin; D. J Triggle; F.. Macdonald (1997). Dictionary of pharmacological agents. CRC Press. p. 1003. ISBN 978-0-412-46630-4. Retrieved 26 November 2011.
- ↑ 3.0 3.1 Index nominum 2000: international drug directory. Taylor & Francis US. 2000. p. 513. ISBN 978-3-88763-075-1. Retrieved 26 November 2011.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||